Skip to main content
Top
Published in: International Journal of Diabetes in Developing Countries 1/2019

01-01-2019 | Original Article

Cost of illness (COI) of type-II diabetes mellitus in Shillong, Meghalaya

Authors: T. Khongrangjem, Sameer Phadnis, Sumit Kumar

Published in: International Journal of Diabetes in Developing Countries | Issue 1/2019

Login to get access

Abstract

This study aimed at contributing to the evidence base of economic burden caused due to type-II DM. The data were obtained from the 158 diabetics from the three tertiary hospitals in Shillong, Meghalaya, during January–March 2017 with the use of a semi-structured questionnaire. The information received was cross-checked with the medical records from the finance department. Patients comprised of 86 (54.4%) females and 72 (45.6%) males. The individuals under the age group of 56–65 were 49 (31%). The total median cost of illness per month was Rs. 5375 (2524–18,968) which was made up of 70.92% direct cost and 29.08% indirect cost. 58.2% respondents used their savings for getting treatment. The cost of care is high and comparable to cost in other countries. An improved understanding of COI of type-II DM will help in informing and motivating the policy and health decision makers which will reduce the national burden of this disease.
Literature
1.
go back to reference Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res. 2007;125:217–30. Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res. 2007;125:217–30.
2.
go back to reference Huizinga MM, Rothman RL. Addressing the diabetes pandemic: a comprehensive approach. Indian J Med Res. 2006;124:481–4.PubMed Huizinga MM, Rothman RL. Addressing the diabetes pandemic: a comprehensive approach. Indian J Med Res. 2006;124:481–4.PubMed
3.
go back to reference Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance. In: Gan D, editor. Diabetes atlas. International Diabetes Federation. 3rd ed. Belgium: International Diabetes Federation; 2006. p. 15–103. Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance. In: Gan D, editor. Diabetes atlas. International Diabetes Federation. 3rd ed. Belgium: International Diabetes Federation; 2006. p. 15–103.
4.
go back to reference Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.CrossRef Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.CrossRef
6.
go back to reference Ali MK, Narayan KM. Innovative research for equitable diabetes care in India. Diabetes Res Clin Pract. 2009;86:155–67.CrossRefPubMed Ali MK, Narayan KM. Innovative research for equitable diabetes care in India. Diabetes Res Clin Pract. 2009;86:155–67.CrossRefPubMed
8.
go back to reference Kessler RC, Petukhova M, McInnes K, Ustün TB. Content and Scoring Rules for the WHO HPQ Absenteeism and Presenteeism Questions. Boston (MA): Harvard Medical School; 2007. Kessler RC, Petukhova M, McInnes K, Ustün TB. Content and Scoring Rules for the WHO HPQ Absenteeism and Presenteeism Questions. Boston (MA): Harvard Medical School; 2007.
9.
go back to reference Riewpaiboon A, Chatterjee S, Piyauthakit P. Cost analysis for efficient management: diabetes treatment at a public district hospital in Thailand. Int J Pharm Pract. 2011;19:342–9.CrossRefPubMed Riewpaiboon A, Chatterjee S, Piyauthakit P. Cost analysis for efficient management: diabetes treatment at a public district hospital in Thailand. Int J Pharm Pract. 2011;19:342–9.CrossRefPubMed
11.
go back to reference Hex N, Barlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29(7):855–62.CrossRefPubMed Hex N, Barlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29(7):855–62.CrossRefPubMed
12.
go back to reference Barcelo A, Aedo C, Rajpathak S and Robles S. The cost of diabetes in Latin America and the Caribbean. Bull World Health Organ. 2003;81(1):19–27. Barcelo A, Aedo C, Rajpathak S and Robles S. The cost of diabetes in Latin America and the Caribbean. Bull World Health Organ. 2003;81(1):19–27.
14.
go back to reference Henriksson F, Agardh CD, Berne C, Bolinder J, Lönnqvist F, Stenström P, et al. Direct medical costs for patients with type 2 diabetes in Sweden. J Int Med. 2000;248(5):387–96. Henriksson F, Agardh CD, Berne C, Bolinder J, Lönnqvist F, Stenström P, et al. Direct medical costs for patients with type 2 diabetes in Sweden. J Int Med. 2000;248(5):387–96.
16.
go back to reference Viswanathan V, Tharkar S, Devarajan A, Kumpatla S. The socioeconomics of a developing country: a population based cost of illness study. Diab Res Clin Pract. 2010;89:334–40.CrossRef Viswanathan V, Tharkar S, Devarajan A, Kumpatla S. The socioeconomics of a developing country: a population based cost of illness study. Diab Res Clin Pract. 2010;89:334–40.CrossRef
17.
go back to reference Anderson Carl R. Locus of control, coping and performance in a stress setting: a longitudinal study. J Appl Psychol. 1977;62:446–51. Google ScholarCrossRef Anderson Carl R. Locus of control, coping and performance in a stress setting: a longitudinal study. J Appl Psychol. 1977;62:446–51. Google ScholarCrossRef
18.
go back to reference Narayan KM, Zhang P, Williams D, Engelau M, Imperatore G. How should developing countries manage diabetes. CMAJ. 2006;175:733–43.CrossRefPubMed Narayan KM, Zhang P, Williams D, Engelau M, Imperatore G. How should developing countries manage diabetes. CMAJ. 2006;175:733–43.CrossRefPubMed
19.
go back to reference The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA 1996;276:1409–15. The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA 1996;276:1409–15.
20.
go back to reference Chatterjee S, Riewpaiboon A, Piyauthakit P, Riewpaiboon W, Bonpaijit K, Panpuwong N, Acharvanuntagal V. Cost of diabetes and its complications in Thailand: A complete picture of economic burden. Health Soc Care Community. 2011;119(3):289–98. Chatterjee S, Riewpaiboon A, Piyauthakit P, Riewpaiboon W, Bonpaijit K, Panpuwong N, Acharvanuntagal V. Cost of diabetes and its complications in Thailand: A complete picture of economic burden. Health Soc Care Community. 2011;119(3):289–98.
22.
go back to reference Dawson KG, Gomes D, Gerstein H, Blanchard JF, Kahler KH. The economic cost of diabetes in Canada, 1998. Diabetes Care. 2002;25(8):1303–7.CrossRefPubMed Dawson KG, Gomes D, Gerstein H, Blanchard JF, Kahler KH. The economic cost of diabetes in Canada, 1998. Diabetes Care. 2002;25(8):1303–7.CrossRefPubMed
23.
go back to reference Rc E, Javitt JC, Herman WH, Dasbach EJ, Zbrozek AS, Dong F, et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care. 1991;20:725–44. Rc E, Javitt JC, Herman WH, Dasbach EJ, Zbrozek AS, Dong F, et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care. 1991;20:725–44.
Metadata
Title
Cost of illness (COI) of type-II diabetes mellitus in Shillong, Meghalaya
Authors
T. Khongrangjem
Sameer Phadnis
Sumit Kumar
Publication date
01-01-2019
Publisher
Springer India
Published in
International Journal of Diabetes in Developing Countries / Issue 1/2019
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-018-0636-z

Other articles of this Issue 1/2019

International Journal of Diabetes in Developing Countries 1/2019 Go to the issue